Top Page
Qyuns Therapeutics Co., Ltd. Class H
(2509)
Qyuns Therapeutics Co., Ltd. Class H (2509) vs. iShares MSCI Hong Kong ETF (EWH)
Qyuns Therapeutics Co., Ltd. Class H Business Overview & Revenue Model
Qyuns Therapeutics Co., Ltd. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 320.36M | 158.79M | 14.75M | 9.66M | 21.35M |
| Gross Profit | 232.06M | 92.19M | 14.75M | -25.85M | -9.56M |
| EBITDA | -156.69M | -311.82M | -484.12M | -295.51M | -155.65M |
| Net Income | -191.79M | -335.57M | -507.75M | -298.19M | -411.04M |
Balance Sheet | |||||
| Total Assets | 1.13B | 983.88M | 795.58M | 1.16B | 1.31B |
| Cash, Cash Equivalents and Short-Term Investments | 558.90M | 556.55M | 377.25M | 689.57M | 620.44M |
| Total Debt | 635.93M | 527.60M | 346.06M | 295.25M | 290.26M |
| Total Liabilities | 916.32M | 762.83M | 494.63M | 419.55M | 444.45M |
| Stockholders Equity | 226.36M | 228.98M | 324.54M | 641.72M | 670.35M |
Cash Flow | |||||
| Free Cash Flow | -213.39M | -186.09M | -308.63M | -301.70M | -228.64M |
| Operating Cash Flow | -211.00M | -186.09M | -300.68M | -275.23M | -157.60M |
| Investing Cash Flow | 109.12M | -25.23M | 243.11M | -5.70M | -306.69M |
| Financing Cash Flow | 133.17M | 351.81M | 61.21M | 211.49M | 281.48M |
Qyuns Therapeutics Co., Ltd. Class H Technical Analysis
Qyuns Therapeutics Co., Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$3.24B | 405.71 | 0.99% | ― | 9.41% | -32.69% | |
52 Neutral | HK$3.40B | -3.23 | ― | ― | 79.98% | -3.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$5.29B | -24.54 | -64.62% | ― | ― | ― | |
44 Neutral | HK$1.08B | -7.58 | ― | ― | ― | 83.89% | |
41 Neutral | HK$1.22B | -1.79 | -51.56% | ― | 2.45% | 2.58% | |
41 Neutral | HK$1.11B | -3.42 | -34.18% | ― | -57.84% | 24.58% |
Qyuns Therapeutics Co., Ltd. Class H Corporate Events
Qyuns Therapeutics Co., Ltd., a Hong Kong-listed Chinese biopharmaceutical company, develops and commercialises therapeutic products and serves investors in the Hong Kong capital market through its H-share listing. The company’s board has initiated on-market share repurchases under an existing mandate, buying back 1,575,800 shares for about HK$31.16 million, representing roughly 0.69% of its issued share capital, citing a belief that the current share price significantly undervalues the company and aiming to bolster market confidence and enhance investment value, while cautioning that any further buybacks will depend on market conditions and remain at the board’s discretion.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
Qyuns Therapeutics has signed a license and collaboration agreement with LE2025 Therapeutics AG, an affiliate of Switzerland-based Windward Bio Group AG, granting LE2025 exclusive rights to develop and commercialize its long-acting anti-TSLPxIL-13 bispecific antibody QX027N outside mainland China, Taiwan, Hong Kong and Macau. Under the deal, Qyuns is eligible to receive up to US$700 million in upfront, equity, development and commercial milestone payments, as well as tiered royalties on QX027N sales in the licensed territories, marking a significant monetisation of its immunology pipeline and expanding the global development footprint of a candidate now in Phase I trials in China, while shareholders are cautioned about trading in the company’s shares.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
Qyuns Therapeutics Co., Ltd. reported that its extraordinary general meeting held on 19 December 2025 in Taizhou, Jiangsu, was duly convened in compliance with PRC law and the company’s articles, with a turnout representing over 70% of H shares with voting rights. Shareholders overwhelmingly approved, by poll, the renewal of the new annual caps for 2026–2028 under the QX001S Framework Agreement for continuing connected transactions, despite the required abstention of significant shareholder Huadong Medicine’s subsidiaries, effectively clearing the way for the company to continue its related-party cooperation arrangements and providing clearer visibility on its transaction limits and governance alignment for the coming three financial years.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
Qyuns Therapeutics Co., Ltd. has received approval from the Human Research Ethics Committee in Australia for a Phase I clinical trial of its bispecific antibody, QX030N/CLD-423, marking a significant milestone in its international clinical development efforts. This approval, accompanied by a $5 million milestone payment from its partner Caldera Therapeutics, underscores the company’s strategic positioning in the field of autoimmune and allergic diseases and highlights its potential for future financial gains through additional milestone payments and royalties.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
Qyuns Therapeutics Co., Ltd. has announced an Extraordinary General Meeting (EGM) scheduled for December 19, 2025, to discuss and approve key resolutions. These include the renewal of the New Annual Caps for financial years 2026 to 2028 under the QX001S Framework Agreement and proposed amendments to the articles of association. The outcomes of this meeting could significantly impact the company’s operational strategies and governance structure, potentially influencing its market positioning and stakeholder interests.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
Qyuns Therapeutics Co., Ltd., a company incorporated in the People’s Republic of China, has announced the closure of its H shares register from December 16 to December 19, 2025, in preparation for an extraordinary general meeting (EGM) scheduled for December 19, 2025. This meeting will allow shareholders whose names appear on the register by December 15, 2025, to attend and vote, indicating a significant event for stakeholder engagement and corporate governance.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
Qyuns Therapeutics Co., Ltd. announced that its long-acting bispecific antibody, QX027N, has received clinical trial approvals for treating asthma and atopic dermatitis, marking a significant milestone in its bispecific antibody pipeline. This development is part of the company’s strategy to advance innovative therapies for respiratory and dermatological diseases, aiming to meet the unmet clinical needs of millions of patients worldwide.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
Qyuns Therapeutics Co., Ltd. has announced the renewal of annual caps for the QX001S Framework Agreement with Zhongmei Huadong, a substantial shareholder holding 15.85% of the company’s issued share capital. This renewal pertains to the commercialization of SAILEXIN (QX001S) and involves continuing connected transactions under the Listing Rules. The renewal is subject to independent shareholders’ approval, with Zhongmei Huadong and its associates required to abstain from voting. The company will dispatch a circular to shareholders detailing the new annual caps, recommendations, and proposed amendments to the articles of association.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
Qyuns Therapeutics Co., Ltd. announced a voluntary on-market share repurchase, indicating that the board believes the current share price undervalues the company’s worth. The repurchase of 549,800 ordinary shares, valued at approximately HK$11.07 million, aims to reinforce market confidence and enhance investment value, though future repurchases will depend on market conditions.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
Qyuns Therapeutics Co., Ltd. has entered into a global exclusive license agreement with Roche, granting Roche the rights to develop, manufacture, and commercialize QX031N. This agreement includes an upfront payment of $75 million to Qyuns and potential milestone payments up to $995 million, along with tiered royalties on future sales. The collaboration is expected to enhance Qyuns’ industry positioning by advancing QX031N as a potential ‘First-in-class’ and ‘Best-in-disease’ therapy for respiratory diseases, potentially impacting stakeholders positively with significant financial and market opportunities.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$24.50 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
Qyuns Therapeutics Co., Ltd. has announced successful Phase III clinical trial results for Crusekitug (QX002N), a treatment for ankylosing spondylitis, presented at the 2025 ACR Annual Meeting. The trial demonstrated significant improvements in clinical symptoms and spinal function, with Crusekitug showing a higher ASAS40 response rate compared to placebo, and favorable safety outcomes. These results position Crusekitug as a promising new treatment option, with the company planning to expedite its registration and market launch.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$24.50 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.